Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2
- JingQi Feng†1,
- Manxin Zhang†1,
- Krystyna Mozdzanowska†1,
- Darya Zharikova1,
- Henry Hoff1,
- William Wunner1,
- Robert B Couch2 and
- Walter Gerhard1Email author
© Feng et al; licensee BioMed Central Ltd. 2006
Received: 08 November 2006
Accepted: 06 December 2006
Published: 06 December 2006
Matrix protein 2 (M2) is an integral tetrameric membrane protein of influenza A virus (IAV). Its ectodomain (M2e) shows remarkably little diversity amongst human IAV strains. As M2e-specific antibodies (Abs) have been shown to reduce the severity of infection in animals, M2e is being studied for its capability of providing protection against a broad range of IAV strains. Presently, there is little information about the concentration of M2e-specific Abs in humans. Two previous studies made use of ELISA and Western blot against M2e peptides and recombinant M2 protein as immunosorbents, respectively, and reported Ab titers to be low or undetectable. An important caveat is that these assays may not have detected all Abs capable of binding to native tetrameric M2e. Therefore, we developed an assay likely to detect all M2e tetramer-specific Abs.
We generated a HeLa cell line that expressed full length tetrameric M2 (HeLa-M2) or empty vector (HeLa-C10) under the control of the tetracycline response element. These cell lines were then used in parallel as immunosorbents in ELISA. The assay was standardized and M2e-specific Ab titers quantified by means of purified murine or chimeric (mouse variable regions, human constant regions) M2e-specific Abs in the analysis of mouse and human sera, respectively. We found that the cell-based ELISA was substantially more effective than immobilized M2e peptide in detecting M2e-specific Abs in sera of mice that had recovered from repetitive IAV infections. Still, titers remained low (< 5 μg/ml) even after two consecutive infections but increased to ~50 μg/ml after the third infection. Competition with free M2e peptide indicated that ~20% of M2e-specific Abs engendered by infection reacted with M2e peptide. In humans presenting with naturally acquired influenza virus infection, 11 of 24 paired sera showed a ≥ 4-fold increase in M2e-specific Ab titer. The Ab response appeared to be of short duration as titers were very low (average 0.2 μg/ml) in all patients at onset of infection and in controls, in spite of evidence for previous exposure to IAV.
The results provide convincing evidence that M2e-specific Ab-mediated protection is currently lacking or suboptimal in humans.
Matrix protein 2 (M2) is a 97 aa-long transmembrane protein of IAV . It contains a 24 aa-long (23 aa after posttranslational removal of the N-terminal Met) non-glycosylated N-terminal ectodomain (M2e). The mature protein forms homotetramers [2, 3] that are displayed at high density (~50% of density of hemagglutinin (HA) trimers) in the plasma membrane of infected cells during the stage of virus maturation [1, 4] but at low density (1–2% of HA) in the membrane of mature virus particles . The protein exhibits pH-inducible proton transport activity and regulates the pH of the viral core during virus entry into the host cell and of transport vesicles that deliver viral transmembrane proteins to the plasma membrane for virus assembly [6, 7].
An important caveat with regard to the low/absent M2e-specific Ab responses is the possibility that previously used assays failed to detect the entire repertoire of M2e-specific Abs. The main M2 immunogen generated in the course of infection is presumably the native M2 homotetramer, but only a fraction of native tetramer-specific Abs may react with denatured M2 protein in Western blot  or monomeric M2e peptides coated onto plastic . To avoid this shortcoming, we previously used virus-infected MDCK cells as immunosorbents to measure the M2e-specific Ab response in mice immunized with M2e-specific vaccines . However, because virus-infected cells express a variety of IAV proteins, this assay could not be used to measure M2e-specific Abs in sera from hosts that have been exposed to IAV. Therefore, we generated an adherent HeLa cell line that stably expressed full-length tetrameric M2 under the control of the tetracycline response element (Tet) and used it as an immunosorbent in ELISA. We found that HeLa-M2 immunosorbents detected higher Ab titers than M2e-peptide immunosorbents in sera of mice immunized by IAV infection. The results indicated that ~80% of the M2e-specific Abs engendered by infection reacted exclusively with cell-expressed (tetrameric) M2e. Still, M2e-specific Ab titers remained low (< 5 μg/ml), even after two consecutive infections, while NP-specific titers reached maximum levels (50–100 μg/ml) after the first infection. Measurement of M2e-specific Ab titers in paired serum samples from the acute and convalescent phase of humans presenting with natural IAV infection revealed a very low M2e-specific Ab titer (average 0.2 μg/ml) in acute serum samples and a ≥ 4-fold increase in only 50% of the patients. Taken together, the results confirmed the generally poor induction of the M2e-specific Ab response by IAV infection and indicated that humans currently lack optimal M2e-specific protection. This provides an important reason for development of an M2e-specific vaccine.
Development of the HeLa-M2 ELISA
Cellular immunosorbents were prepared in flat bottom 96-well polystyrene plates as described in the Method section. The cells were cultured for 2 days in the presence of doxycycline and then fixed for 20 min with 0.05% glutaraldehyde and stored in the refrigerator with PBSN-1% BSA medium until used for assay. The plates could be stored for several weeks without major loss of antigenic activity (Figure 2B). Glutaraldehyde-fixed HeLa cells exhibited a high endogenous alkaline phosphatase activity that could not be inhibited by levamisol (data not shown) but a low endogenous peroxidase activity. This made the use of a peroxidase-based ELISA system highly preferable.
Taken together, the results showed that HeLa-M2 cells expressed tetrameric M2 and, following glutaraldehyde fixation, formed sensitive immunosorbents that were quite stable over several weeks of storage at 4°C.
HeLa-M2 cells are more effective than M2e peptide immunosorbents in detecting M2e-specific Abs in sera of infection-immunized mice
Analysis of M2e- and NP-specific Ab responses engendered in mice by infection
Analysis of M2e- and NP-specific Ab responses in humans undergoing a natural IAV infection
Previous studies indicated poor M2e-specific Ab responses following IAV infection in mice [11, 13] and humans [19, 20]. It was not clear, however, whether the low responses reflected the inability of the previously used assays to detect the entire repertoire of M2e-specific Abs or whether the M2 presented to the immune system in the context of an infection is poorly immunogenic. To resolve this issue, we developed an ELISA that used M2-transfected HeLa cells as immunosorbent. Assuming that HeLa-cells expressed M2 in the same form as virus-infected host cells, this cellular immunosorbent would be expected to detect all biologically relevant M2-specific Abs. HeLa-M2 cells were shown to express tetrameric M2 (Fig 4A) and were found to be superior to immobilized M2e peptide immunosorbent in detecting M2e-specific Abs induced in mice by repetitive infections (Fig 5C). However, in spite of the improved assay, the HeLa-M2 ELISA reaffirmed that the M2e-specific Ab response was poorly induced by infection. Thus, three consecutive infections were required to raise M2e-specific Ab titers in mice to the level (~50 μg/ml) reached in the NP-specific response after a single infection (Fig 8). In humans, natural infection resulted in a ≥ 4-fold increase in M2e-specific Ab titers in 45% of subjects. However, if induced, the response appeared to be of short duration as M2e-specific Ab titers were very low or undetectable in serum samples obtained from the acute phase of the infection or from controls. Thus, the study confirmed that IAV infection in mouse and human induced a poor M2e-specific Ab response and, more importantly, that humans lacked significant M2e-specific Ab-mediated protection.
Competition binding studies indicated that ~20% of the infection-induced M2e-specific Ab response (in a pooled serum from four mice) that reacted with HeLa-M2 cells, crossreacted with monomeric M2e-peptide. This is most likely the fraction of the total response to native M2e-tetramer that is detected by ELISA using M2e-peptide immunosorbent and is induced by immunization with M2e peptide vaccines that display M2e-peptides in monomeric form.
Although the majority (~80%) of infection-induced M2e-specific Abs did not react with monomeric M2e-peptide, none of the M2e-specific MAbs generated in our laboratory from infection-primed mice reacted exclusively with M2 tetramer (data not shown). This can be explained by the fact that all lymphocyte donor mice were boosted with M2e-MAP prior to fusion – to increase the probability of isolating M2e-specific hybridomas  – and initial hybridoma cultures had to be screened for M2e-specific Ab secretion by ELISA against M2e-peptide immunosorbent as the HeLa-M2 cell line was not available at the time. We are currently attempting to isolate M2e tetramer-specific hybridomas from infection-immunized mice without peptide boost and using the HeLa-M2 ELISA for screening. Holsinger and Lamb, 1991  described an MAb that reacted in Western blot with M2 dimer but not M2-monomer and appears to be a member of this dominant M2-polymer-specific Ab group.
The reason for the low M2e-specific Ab response induced by infection remains unknown but the following two factors are likely to contribute. First, the number of naive M2e-specific precursor B cells may be very small and their expansion into a sufficiently large population of M2e-specific Ab-secreting and memory B cells may require several rounds of stimulation. This is consistent with the finding that three consecutive infections in mice were required for induction of M2e-specific Ab titers in the range of 50 μg/ml. It is consistent also with the small size of the antigenic region of M2e. Indeed, the latter may comprise ≤ 15 amino acids [16, 20, 22], which is in the lower size range of a typical protein epitope recognized by an individual Ab . The small size of the antigenic determinant would be expected to restrict the number of unique combinations of V gene segments that interact strongly with it and thus the number of M2e-reactive B cells in the naive repertoire . Second, antigenic competition by the much more numerous HA- and NA-specific B cells for a limited amount of immunogenic entities may further suppress the M2e-specific Ab response. To participate in a Th-dependent Ab response, antigen-specific B cells must capture the specific antigen with their membrane Ig, internalize and process it and finally display its associated helper T cell determinants to permit cognate interaction with activated helper T cells. As the immunogenic M2e entities may consist predominantly of membrane fragments that contain also associated HA and NA molecules, the much more numerous HA- and NA-specific precursor B cells would be expected to capture and consume most M2, leaving little for stimulation of the few M2e-specific precursor B cells. Antigenic competition by HA-specific precursor B cells has been shown to suppress the NA-specific Ab response both in humans  and mice . The phenomenon of antigenic competition was shown to depend on the physical linkage between competing antigens [26, 27] and could be modified by prior immunization against one of the component antigens [27, 28]. The fact that good M2e-specific responses can be induced by immunization with isolated M2e antigen constructs supports a role for antigenic competition in the low M2e-specific Ab response. Still, assuming that most of the adult human serum donors analyzed in this study had experienced several previous IAV infections and in view of the sizeable M2e-specific response seen in mice after three consecutive infections (Fig 8), the low M2e-specific Ab titers in adult human sera are nevertheless surprising. Perhaps induction of substantial and long lasting M2e-specific Ab responses requires massive and consecutive pneumonias as was the case in the experimental mice but may occur only rarely in humans.
The study showed that on average only ~20% of the M2e-specific Abs, generated in mice by repetitive IAV infections and capable of binding to M2-transfected HeLa cells, reacted also with monomeric M2e peptide. Use of the M2-transfected HeLa cell-based ELISA for determination of M2e-specific Ab titers in human sera convincingly showed that M2e-specific Ab-mediated protection is currently subpoptimal or absent in humans. This provides a strong incentive for the development of an M2e-specific vaccine.
Media and solutions
ISC-CM is Iscove Dulbecco medium (Invitrogen) supplemented with 0.05 mM 2-mercaptoethanol, 0.005 mg/ml transferrin (Sigma), 2 mM L-glutamine (Mediatech-Cellgro) and 0.05 mg/ml gentamicin (Mediatech-Cellgro). ISC-CM was further supplemented with fetal calf serum (FCS, Hyclone Laboratories) or bovine serum albumin (BSA, Sigma) at the indicated concentrations. PFHM-II is protein-free hybridoma medium (Invitrogen). TCRM is phosphate-buffered (pH7.2) potassium/sodium saline supplemented with 2.5 mM EDTA. PBSN is phosphate buffered saline (pH7.2) supplemented with 3 mM NaN3.
Human and mouse sera
Acute and convalescent sera from humans were obtained during an influenza therapeutic trial in the winter of 1985. Subjects were healthy young adults who presented within 24 hours of onset of clinical influenza with fever (≥ 100°F). Respiratory secretion samples from each subject yielded influenza A (H3N2) virus and paired sera exhibited a significant increase in hemagglutination-inhibiting (HI) antibody between the acute and convalescent sampling. Before submitting the sera for testing for M2e-specific antibody, the HI titers detected in a subset of the sera were confirmed to be unchanged from the original titers. Exempt status (EX2409036-1) for the measurement of Ab titers in blinded paired sera from these studies was granted by the Institutional Review Board of the Wistar Institute,
Naive mouse serum (NMS) was obtained from BALB/c mice. Pooled plasma or serum was obtained from convalescent BALB/c mice (2–5 per group) 21–28 days after primary total respiratory tract infection with A/PR/8/34(H1N1)-Mt.S-Wi (PR8), 10–28 days after secondary and 7–37 days after tertiary infection. The viruses used for consecutive infection shared the same M2e sequence but differed in HA sequence to bypass extant HA-specific immunity . Plasma and serum were also obtained from BALB/c mice that had been inoculated twice by the intranasal or subcutaneous routes with the multiple antigenic peptide vaccine (4)M2e-MAP . An antiserum specific for the intracytoplasmic C terminus of M2 was produced by immunization of mice with the linear peptide T2M2C (AQYIKANSKFIGITEDADDGHFVSIELE, firstname.lastname@example.org), which contains on its N-terminus the helper determinant of tetanus toxoid (830–843)  and on its C terminus the intracytoplasmic C terminus of M2 of PR8 (underlined in the linear peptide). Ten μg T2M2C, 1 μg cholera toxin (Sigma) and 5 μg immunostimulatory oligodeoxynucleotide 1826 , emulsified in 100 μl PBS/50% incomplete Freund adjuvant, were injected twice (3 week interval) into the tail base of five BALB/c mice. Plasma was obtained three weeks after the second injection and pooled. All protocols for animal experiments were approved by the Animal Care and Use Committee of the Wistar Institute.
Expression of M2 in HeLa Tet-on cells
Full-length M2 cDNA of PR8 was cloned into the BamHI/EcoR V restriction site of pENTR™ TOPOR vector (Invitrogen) and the insert verified by sequence analysis. M2 was subsequently cloned into the BamHI/EcoR V site of the Tet-on response vector pTRE2pur (BD Biosciences) to produce pTRE2pur-M2. A HeLa cell line, stably transfected with the pTet-On regulatory plasmid (BD Biosciences), was maintained in ISC-CM supplemented with 10% Tet system approved FBS (Tet-FBS) (BD Biosciences) and 500 μg/ml G418. For transfection, 105 Tet-On HeLa cells per ml OptiMem medium were seeded into wells of a 6-well plate and transfected with 4 μg pTRE2pur-M2 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 24 hrs, the cells were resuspended in ISC-CM supplemented with 10% Tet-FBS and 0.5 μg/ml puromycin (BD Biosciences), transferred into 100 × 20 mm petri dishes and maintained in an air/CO2 incubator for 2 weeks. Forty well-growing colonies of adherent HeLa cells were harvested by overlaying individual, well separated, colonies with cloning discs (PGC Scientific) soaked with trypsin-versene medium (Sigma) and transferring the disks with adherent cells to individual culture dishes. Replicate samples of individual colonies were seeded into 96-well plates, cultured for 2 days in ISC-CM-10%FCS supplemented with doxycycline (1 μg/ml, BD Biosciences) and then tested by ELISA for expression of M2. The colony with the highest expression level of M2 was selected and expanded in ISC-CM supplemented with 10% Tet-FBS, 0.5 μg/ml puromycin and 500 μg/ml G418. The cell line is reported here as HeLa-M2. A control HeLa cell line stably transfected with empty pTRE2pur was similarly generated and a clone (HeLa-C10) selected based on good growth rate in the presence of the selection marker puromycin.
ELISA using HeLa-M2 and HeLa-C10 cells
Cells were released from confluent monolayers in T75 flasks by incubation with TCRM and vigorous tapping of the flask. Released cells were suspended at 105/ml in ISC-CM supplemented with 10% FBS and 1 μg/ml doxycycline and dispensed (150 μl/well) into flat bottom 96-well Microtest™ plates (Falcon). After 2 days of incubation at 37°C in air/CO2, when the cells had formed closed monolayers, the medium was flicked out and the monolayers were fixed by incubation for 20 min at room temperature with 100 μl 0.05% glutaraldehyde in PBS. The glutaradehyde was then flicked out, the monolayers washed with PBSN and incubated with PBSN-1% BSA (~150 μl/well) for blocking and storage of the plates in the refrigerator.
For ELISA, plates were washed once with PBSN and then sequentially incubated with serum dilutions, biotinylated rat anti-mouse Cκ-specific MAb 187 (ATCC HB58) or a mixture of goat-anti-human Cκ and Cλ-specific antisera (Southern Biotech), streptavidin-peroxidase polymer (Sigma) and o-phenylenediamine dihydrochloride (OPD, Sigma). Sera were diluted in PBSN containing 0.5% gelatin (Sigma) and 0.5% skim milk and tested in triplicate or quadruplicate aliquots at 50 μl/well. Reagents were diluted in PBSN-1% BSA and used at 50 μl/well except for OPD, which was diluted in Sigma Fast buffer and used at 100 μl/well. All washes between sample applications were done with PBSN. The assay was stopped by addition of 50 μl 2 M HCl/well and OD read with the Emax microplate reader (Molecular Devices, Sunnyvale, CA) at 490 and 750 nm and the difference (OD490–750) recorded. Assays were performed in parallel on HeLa-M2 and HeLa-C10 immunosorbents, both present in the same assay plate, and the difference in OD490–750 between HeLa-M2 and HeLa-C10 computed and recorded as ΔOD. This was necessary because sera, particularly when used at low dilution, displayed substantial and individually distinct levels of background binding as revealed by reaction with HeLa-C10 (background binding was lower when the assay was developed with IgG heavy chain-specific Ab reagents, presumably because Abs of IgM isotype make a dominant contribution to assay background). Assays of murine and human sera were quantified by titration of known concentrations of purified M2e-specific MAb 14C2-S1-4 and the human-mouse chimeric MAb TRF-3.1 (see below), respectively. Data were analyzed with the Softmax software (Molecular Devices).
Competitive binding assay
The assay was essentially performed as described by Zhang et al., 2006 , except for using HeLa cell immunosorbents instead of M2e-peptide immunosorbents. In brief, dilutions of M2e-peptide were mixed with a constant dose of serum or MAb, incubated for 45 min and then transferred to HeLa-M2 and HeLa-C10 immunosorbents. After 45 min incubation, samples were removed and bound Ab detected as in the HeLa ELISA described above. The competing peptide was (2)M2e-MAP, which contains 2 chains of M2e(2–24) attached to a linear Cys-Gly-(Lys-Gly)4-Ala backbone .
Trypsin treatment and permeabilization of HeLa immunosorbents
Glutaraldehyde-fixed and BSA-blocked HeLa cell monolayers were extensively washed with warm (37°C) PBS and then incubated for 30 min at 37°C with dilutions of trypsin (2.5%, Gibco) in PBS ranging in 2-fold steps from 1/8 to 1/64. The trypsin was then rinsed off and the immunosorbents were compared by ELISA to untreated HeLa cell monolayers for binding of a saturating dose of M2e-specific MAb or mouse antiserum raised against T2M2C, which contained Abs specific for the intracytoplasmic C-terminus of M2. Glutaraldehyde-fixed and BSA-blocked HeLa-M2 immunosorbents were permeabilized by incubation for 10 min at room temperature with PBSN containing 0.5% NP40. Detergent was then rinsed off and the plates were used in ELISA as described above.
Analysis of HeLa-M2 by SDS PAGE and Western blot
HeLa-M2 and HeLa-C10 cell monolayers were cultured for 2 days in 6-well cluster plates as described above for preparation of ELISA plates but using 2 ml cell suspension/well. Monolayers were fixed with glutaraldehyde or left unfixed. Monolayers were incubated with 0.5 ml lysis buffer, the lysate was sonicated and electrophoresed under non-reducing conditions in a preformed 10% Tris-Bis polyacrylamide gel (NuPage, Invitrogen) with MES running buffer. The gel was blotted onto a PVDF membrane (Invitrogen). The membrane was blocked with PBSN-1%BSA and stained by sequential incubation with M2e-specific MAb 14C2, biotinylated anti-Cκ MAb 187, streptavidin-peroxidase and diaminobenzidine.
Expression and purification of recombinant nucleoprotein (rNP)
Full-length NP cDNA of PR8 with 5' EcoRI and 3' NotI restriction sites was inserted into the EcoRI/NotI site of pFast Bac1 HTA vector (Invitrogen), which will encode NP with N-terminal 6xHis tag and intervening TEV recognition site for subsequent enzymatic removal of the His tag. Recombinant baculovirus expressing full-length NP was generated and grown in Sf9 cells. rNP was isolated from infected Sf9 cell lysates using the Y-PER™ 6xHis Column Purification Kit (Pierce) according to the manufacturer's instructions. Purified rNP was quantified by BioRad protein assay and light absorption at 280 nm.
Purified rNP (with 6xHis tag) was diluted to 5 μg/ml in 0.02 M NaCl and 25 μl samples were dispensed into 96-well round bottom Serocluster™ polyvinyl plates. The plates were covered with plastic sheets to avoid evaporation, incubated overnight at room temperature and then blocked for 1 hr by incubation with PBSN-1% BSA before use in ELISA. The ELISA procedure was as indicated above for the HeLa ELISA except that 25 μl volumes were used for serum dilutions and reagents and 50 μl for substrate. All samples were tested in parallel against wells coated with rNP and against uncoated BSA-blocked control wells and ΔODs were computed. In the case of human sera, binding activity was expressed relative to serum 12B, which was included as standard in each assay and was assigned an arbitrary NP-specific Ab concentration of 100. In the case of mouse sera, binding activity was expressed relative to purified NP-specific MAb L39-17.
The multiple antigenic peptide consisting of a Cys-(Gly-Lys)3-Ala backbone with two attached M2e(2–24) peptides was used to coat wells of 96-well Microtest™ plates (Falcon) by incubation of 50 μl peptide dilution in 0.02 M NaCl overnight at room temperature. The ELISA was performed as described above for the HeLa-M2 assay.
Generation of M2e-specific chimeric mouse-human MAb
Cloning of light (L) and heavy (H) chain variable (V) regions of the M2e-specific MAb M2-56, including signal sequences, into the TOPO TA vector (Invitrogen) has been described . VL cDNA was amplified with Taq DNA polymerase (Promega) using a forward primer that hybridized to the leader sequence of the VL region and contained a Kozak recognition site and EcoR V restriction site 5' of the initiation codon (5' GGGGAT ATC CCACC ATG GAGT CACAGA CTCAG 3'; EcoR V site underlined and initiation codon in bold letters) and a reverse primer that hybridized to the Jκ 1 region and contained a Sal I restriction site (5' GTAAGTCGAC TTACGTTT GATTTCCAGCTTGGTGCC 3'; restriction site underlined, terminal Jκ 1 codon in bold, intervening sequence to provide correct splice site). The PCR product was inserted into the TOPO TA vector and the cloned insert confirmed by EcoR I digestion and sequencing. The TOPO TA vector was then digested with EcoR V and Sal I restriction enzymes (NEB), the VL fragment purified by agarose gel electrophoresis and ligated with T4 DNA ligase (NEB) into the EcoR V/Sal I site of the expression vector pAG4622 . The ligation reaction was transformed into E.coli HB101 competent cells (Promega). Ampicillin-resistant colonies were selected on LB agar and amplified in LB/ampicillin medium. Plasmid was extracted with the Qiagen miniprep kit and screened for presence of an insert of correct size by digestion with EcoR V and Sal I and agarose gel electrophoresis. Inserts of selected clones were confirmed by sequence analysis. The resulting expression vector was designated pAG-LK56.1. A similar procedure was followed for cloning of VH into the expression vector pAZ6860 . VH was amplified with the forward leader sequence primer (5' GGGGATATC CCACC ATG GGTTGGAGCTGTATCATC 3'; 5' flanking EcoRV site underlined) and the reverse JH3 primer (5' GTAGCTAGC TGC AGAGACAGTGACCCAGAGT 3'; Nhe I restriction site underlined and last 3' JH3 codon in bold). The PCR product was purified, digested with EcoR V and Nhe I and ligated into the EcoR V/Nhe I site of expression vector pAZ6860. This resulted in the expression vector pAZ-LH56. 106 X63-Ag8.653 cells  in OptiMem were transfected with pAG-LK56.1 and pAZ-LH56 using Fugene 6 (Roche) according to the manufacturer's protocol. The cells were cultured for 2–3 days in OptiMem with 10% FCS and subsequently in medium supplemented with the selection marker zeocin (1 mg/ml). After 2 weeks, residual viable cells were cloned in the same medium by limiting dilution. Medium from well growing clones was tested by ELISA for concentration of M2e-specific Ab, using biotinylated goat-anti-human Cκ-specific antiserum for detection of bound Ab. The clone with highest secretion of M2e-specific MAb (TRF-3.1) was selected.
Purification of chimeric M2e-specific MAb
TRF-3.1 cells were expanded in ISC-CM supplemented with 5% FCS and Zeocin (1 mg/ml). Cells from dense cultures were pelleted and cultured to exhaustion (~90% cell death) in protein-free PFHM-II medium without zeocin. Cells and debris were pelleted, and chimeric MAb was purified from the medium by adsorption to and elution from a protein G column (Pierce).
This study was supported by NIAID grant AI46457 (WG) and contract NO1-AI-30039 (RBC) and the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health. We are thankful to Sherrie Morrison for providing us with the human light and heavy chain constant region expression plasmids and to Natasha Levenkova of the Wistar Institute's Bioinformatics core facility for developing a program to analyze M2e sequences deposited in public data banks.
- Lamb RA, Zebedee SL, Richardson CD: Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985,40(3):627-633. 10.1016/0092-8674(85)90211-9View ArticlePubMedGoogle Scholar
- Holsinger LJ, Lamb RA: Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991,183(1):32-43. 10.1016/0042-6822(91)90115-RView ArticlePubMedGoogle Scholar
- Sugrue RJ, Hay AJ: Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991,180(2):617-624. 10.1016/0042-6822(91)90075-MView ArticlePubMedGoogle Scholar
- Mozdzanowska K, Maiese K, Furchner M, Gerhard W: Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999,254(1):138-146. 10.1006/viro.1998.9534View ArticlePubMedGoogle Scholar
- Zebedee SL, Lamb RA: Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988,62(8):2762-2772.PubMed CentralPubMedGoogle Scholar
- Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell 1992,69(3):517-528. 10.1016/0092-8674(92)90452-IView ArticlePubMedGoogle Scholar
- Sugrue RJ, Bahadur G, Zambon MC, Hall-Smith M, Douglas AR, Hay AJ: Specific structural alteration of the influenza haemagglutinin by amantadine. Embo J 1990,9(11):3469-3476.PubMed CentralPubMedGoogle Scholar
- Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP: Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993, 74 ( Pt 1): 143-146.View ArticleGoogle Scholar
- Liu W, Li H, Chen YH: N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003,35(2):141-146. 10.1016/S0928-8244(03)00009-9View ArticlePubMedGoogle Scholar
- Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr., Gerhard W: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003,21(19-20):2616-2626. 10.1016/S0264-410X(03)00040-9View ArticlePubMedGoogle Scholar
- De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W: Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005,337(1):149-161. 10.1016/j.virol.2005.04.004View ArticlePubMedGoogle Scholar
- Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999,5(10):1157-1163. 10.1038/13484View ArticlePubMedGoogle Scholar
- Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW: Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004,22(23-24):2993-3003. 10.1016/j.vaccine.2004.02.021View ArticlePubMedGoogle Scholar
- Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP: Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J Gen Virol 1993, 74 ( Pt 8): 1673-1677.View ArticleGoogle Scholar
- Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995,13(15):1399-1402. 10.1016/0264-410X(95)92777-YView ArticlePubMedGoogle Scholar
- Zhang M, Zharikova D, Mozdzanowska K, Otvos L, Gerhard W: Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Mol Immunol 2006,43(14):2195-2206. 10.1016/j.molimm.2005.12.015View ArticlePubMedGoogle Scholar
- Padlan EA: X-ray crystallography of antibodies. Adv Protein Chem 1996, 49: 57-133.View ArticlePubMedGoogle Scholar
- Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr., Ogra PL: Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 1987,138(9):3010-3013.PubMedGoogle Scholar
- Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED: Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 1987,139(6):2010-2014.PubMedGoogle Scholar
- Johansson BE, Kilbourne ED: Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 1993,67(10):5721-5723.PubMed CentralPubMedGoogle Scholar
- Schutze MP, Deriaud E, Przewlocki G, LeClerc C: Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989,142(8):2635-2640.PubMedGoogle Scholar
- Johansson BE, Kilbourne ED: Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc Natl Acad Sci U S A 1994,91(6):2358-2361. 10.1073/pnas.91.6.2358PubMed CentralView ArticlePubMedGoogle Scholar
- Demotz S, Barbey C, Corradin G, Amoroso A, Lanzavecchia A: The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 1993,23(2):425-432.View ArticlePubMedGoogle Scholar
- Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000,164(3):1617-1624.View ArticlePubMedGoogle Scholar
- Coloma MJ, Hastings A, Wims LA, Morrison SL: Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992,152(1):89-104. 10.1016/0022-1759(92)90092-8View ArticlePubMedGoogle Scholar
- Kearney JF, Radbruch A, Liesegang B, Rajewsky K: A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979,123(4):1548-1550.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.